Home/Specialties/Oncology
Oncology Billing & RCM

Oncology billing and revenue cycle, 50-state coverage.

Oncology billing and revenue cycle services from ASP-RCM Solutions. 13,631 NPPES oncology billing providers across all 50 states + DC. HIPAA + SOC 2 Type II compliant. Senior partners on every account.

Free oncology billing audit → See 50-state coverage

What good oncology billing execution looks like.

The operating discipline we install on every oncology billing engagement.

  1. Infusion and chemotherapy administration code accuracyOncology infusion billing requires precise capture of initial, sequential, concurrent, and additional hour codes (96360-96376, 96401-96450, J-codes for drugs). Infusion centers leak revenue on undercoded administration time.
  2. J-code drug pricing and ASP+6 reimbursementOncology drugs reimburse under Medicare at Average Sales Price + 6 percent (Part B), with similar logic on many commercial. Oncology practices need accurate J-code billing, NDC reporting, and ASP-aware revenue forecasting.
  3. Prior authorization for oncology drugsSpecialty oncology drugs require payer prior authorization, often with clinical criteria tied to NCCN guideline alignment. PA automation tuned for oncology compresses access-to-treatment time and reduces denials.
  4. E/M leveling for oncology visitsOncology visits qualify for higher E/M levels under MDM complexity rules. Oncology practices that under-level E/M leave significant revenue uncollected.
  5. OCM and Enhancing Oncology Model participationPractices in the CMS Enhancing Oncology Model (EOM) coordinate clinical, financial, and reporting workflows for value-based payment. EOM participants need RCM that flows into program reporting.
  6. 340B drug pricing for eligible oncology entitiesFQHC + DSH-eligible hospital oncology practices in 340B require precise inventory tracking, contract pharmacy coordination, and proper claim modification (TB modifier).

Drug and administration revenue map

One infusion visit pays twice. Most practices only collect once and a half.

There is no oncology dashboard screenshot to show you here, so we drew the exhibit instead. Everything plotted below is current federal payment rule and published CPT structure, not sample data and not a client.

Oncology drug and administration revenue map ONE INFUSION VISIT PAYS TWICE: THE DRUG AND THE TIME IN THE CHAIR A. THE ADMINISTRATION CLOCK push 96413 96413 + 96415 96413 + 96415 x 2 015 min1h 302h 303h 30 An infusion of 15 minutes or less is reported as an IV push, not an infusion, which for chemotherapy is 96409.Each additional hour is added only once the infusion runs more than 30 minutes past the previous hourincrement. A different drug run sequentially through the same access adds 96417, once per sequential drug. LEAK 1 Start and stop times sit in the nursing record and never become 96415 or 96417 units on the claim.The hierarchy gets lost too: chemotherapy outranks therapeutic infusion, which outranks hydration. B. THE VIAL Amount administered Amount discarded one vial single-dose container CLAIM LINE 1 J-code, 11-digit NDC in 5-4-2 format,unit qualifier and units administered CLAIM LINE 2 Same J-code with modifier JW,units discarded When nothing is discarded the line carries modifier JZ instead. Since October 1, 2023 a single-dose containerclaim that reports neither modifier can be returned as unprocessable until it is resubmitted correctly. LEAK 2 Waste is discarded at the chair and never captured, so the JW line is never created at all, or theattestation modifier is missing and an otherwise clean claim comes back unprocessable. THE GATE None of the above pays if the regimen is not authorized. High-cost regimens carry payer prior authorizationtied to a named agent, so a mid-cycle regimen change can void the authorization already on file. The drug reimburses on average sales price. The chair time reimburses on the clock. Both have to leave on the same claim.

Sources: administration code structure and the 15-minute push rule from the AMA CPT drug administration guidelines and the CMS Medicare Claims Processing Manual, Chapter 12, section 30.5; JW and JZ modifier policy and the October 1, 2023 claim edit from CMS, Discarded Drugs and Biologicals, JW Modifier and JZ Modifier Policy. Codes are shown to illustrate structure, not to substitute for the current code set.

The rules that govern an oncology claim

Six oncology numbers your business office should know cold.

Each figure below carries its source. We do not publish benchmarks we cannot point at.

106%
Part B drug payment limit

Most separately payable Part B drugs are paid at 106 percent of the volume-weighted average sales price. The limit for a quarter is built from manufacturer ASP data reported two quarters earlier, so acquisition cost on a fast-moving drug can outrun the limit.

Social Security Act 1847A; CMS quarterly ASP pricing files
JW / JZ
The modifier pair, not a choice

JW reports the discarded amount of a single-dose container drug. JZ attests there was none. From October 1, 2023 a claim reporting neither can be returned as unprocessable.

CMS, Discarded Drugs and Biologicals, JW and JZ Modifier Policy
15 min
Where an infusion stops being one

An administration of 15 minutes or less is reported as an IV push rather than an infusion. Above that, the clock drives the code, and the additional hour only lands once the infusion runs more than 30 minutes past the previous hour increment.

AMA CPT drug administration guidelines; CMS Claims Processing Manual, Ch. 12 sec. 30.5
One
Initial code per encounter

Only one initial administration service is reported per encounter unless two separate intravenous sites are medically reasonable and necessary. Everything else on the visit is an additional, sequential or concurrent unit.

CMS Medicare Claims Processing Manual, Chapter 12, section 30.5
$110
EOM monthly payment, per beneficiary

The Enhancing Oncology Model base Monthly Enhanced Oncology Services payment rose from $70 to $110 per beneficiary per month effective January 1, 2025, with a further $30 for dually eligible beneficiaries. Six-month episodes are triggered by chemotherapy across seven cancer types.

CMS Innovation Center, Enhancing Oncology Model
13,631
Oncology orgs in NPPES

Oncology billing organizations registered across all 50 states and DC. ASP-RCM publishes a field guide for every one of them.

NPPES registry, ASP-RCM specialty universe build

The Enhancing Oncology Model runs to June 30, 2030 for both cohorts, with the second cohort having started July 1, 2025. Participation reporting is a revenue cycle obligation, not only a clinical one, because the monthly payment and the episode reconciliation both key off claim data your billing operation produces.

Revenue leakage taxonomy

The five places oncology revenue actually leaks.

Oncology leaks are quiet because the claim usually pays. It pays for fewer units than the visit earned, or it pays for the drug and not the waste, and the difference never shows up as a denial.

Leakage driverHow it actually happensThe control we installWhere it is caught
Undercoded administration time96413, 96415, 96417The nursing record carries hang time and stop time. The claim carries an initial hour and nothing else. Sequential infusions of a second agent through the same access go unreported, and additional hour units are dropped because nobody reconciled the clock to the units.Administration start and stop times reconciled to units before the claim goes out, with the infusion hierarchy applied so the correct service is the initial one and the rest fall in as sequential or concurrent.Pre-bill
Unbilled drug wasteModifier JW and JZThe remainder of a single-dose container is discarded at the chair and never recorded, so the JW line is never created. Or nothing is discarded and the JZ attestation is simply omitted, which since October 1, 2023 can push the claim back as unprocessable.Vial-level waste capture at the point of administration, with the JW or JZ decision forced at the line rather than left to the coder, and reconciliation of dispensed units against billed units.At the chair
NDC and unit-of-measure defects11-digit, 5-4-2The J-code goes out without the 11-digit NDC, with the wrong unit qualifier, or with an NDC quantity that does not reconcile to the HCPCS units. State Medicaid programs collect NDC data on physician-administered drugs to claim manufacturer rebates, so the defect is a hard stop rather than a rounding issue.An NDC to HCPCS crosswalk with the unit conversion validated pre-bill, so package units and billing units reconcile on every drug line rather than on the ones somebody remembered to check.Pre-bill
Prior authorization driftHigh-cost regimensAuthorization is obtained for the regimen as first written. The regimen changes mid-cycle, a new agent enters, and the authorization on file names the old one. The infusion is delivered and the drug is already in the patient before anyone reads the denial.Authorization tracked against the regimen rather than the patient, re-verified at every regimen change and at every dose escalation, with the treating team told before the chair is booked rather than after.Before the chair
ASP lag on acquisitionBuy and bill marginThe payment limit for a quarter is built from average sales price data reported two quarters earlier. On a drug whose acquisition cost is moving, the practice can buy above what Medicare will pay and only discover it when the quarter closes.Acquisition cost tracked against the current quarter payment limit at the drug level, so a negative-margin agent is a purchasing decision that gets made deliberately rather than a surprise at month end.Quarterly

Citations for this table: payment methodology from Social Security Act 1847A and the CMS quarterly ASP pricing files; discarded drug modifiers from CMS, Discarded Drugs and Biologicals, JW Modifier and JZ Modifier Policy; NDC reporting on physician-administered drugs from Social Security Act 1927(a)(7); administration coding structure from the AMA CPT drug administration guidelines and the CMS Medicare Claims Processing Manual, Chapter 12, section 30.5.

Money map

From regimen ordered to cash posted.

Five stages. Three leak points. All three sit upstream of the clearinghouse, which is why working oncology denials after submission never gets a practice to a clean net collection rate.

Oncology regimen to cash money map 0102030405 Regimen orderedand authorized Drug drawn from asingle-dose vial Infusion delivered,times documented Coded: J-code, NDC,administration units Payment postedand reconciled LEAKLEAKLEAK Authorization namesthe prior agent aftera mid-cycle change Start and stop timesnever become extrahour or sequential units Waste unreported, orNDC units do notreconcile to J-code units Every one of these is knowable before the claim leaves the building.After submission it is appeals work, recovered at a fraction of the rate and months later.

Top oncology billing markets by NPPES org count.

State-level RCM guides for the largest oncology billing markets in the U.S.

California1,417 orgs → Florida1,401 orgs → New York1,005 orgs → Texas974 orgs → Maryland670 orgs → Pennsylvania643 orgs → New Jersey581 orgs → Michigan495 orgs →

View all 50 state guides →

Oncology billing FAQ

Questions oncology practice leaders actually ask.

What is the difference between the JW and JZ modifiers?

Both describe what happened to the remainder of a single-dose container drug. JW reports the amount that was discarded and not administered to any patient, so the practice is paid for that portion. JZ attests that there was no discarded amount at all. They are a pair rather than a choice: every eligible single-dose container line carries one or the other, and since October 1, 2023 a claim that reports neither can be returned as unprocessable until it is resubmitted correctly.

How does Medicare pay for oncology drugs under Part B?

Most separately payable Part B drugs are paid at 106 percent of the volume-weighted average sales price for the billing code. The payment limit is refreshed quarterly from average sales price data that manufacturers reported two quarters earlier, which means the limit in force today reflects a market that has already moved. On a drug whose acquisition cost is rising, a practice can buy above what Medicare will pay and not see it until the quarter reconciles, so acquisition cost belongs on the same report as the payment limit.

When is chemotherapy administration reported as an infusion rather than an injection?

The clock decides. An administration of 15 minutes or less is reported as an intravenous push rather than an infusion. Beyond that the initial hour is reported once, and an additional hour is only added when the infusion runs more than 30 minutes past the previous hour increment. A different drug run sequentially through the same access adds a sequential infusion unit. Only one initial service is reported per encounter unless two separate intravenous sites are medically reasonable and necessary, and the hierarchy matters: chemotherapy administration outranks therapeutic infusion, which outranks hydration.

Why does an oncology claim need the NDC when it already carries a J-code?

Because the J-code identifies the billing unit and the National Drug Code identifies the actual product that was drawn. State Medicaid programs are required to collect National Drug Code data on physician-administered drugs so they can claim manufacturer rebates, and many commercial payers now follow. The code has to be the 11-digit form in 5-4-2 format, with the correct unit qualifier and a quantity that reconciles to the units billed against the J-code. When the package units and the billing units do not reconcile, the line does not pay, and no amount of appeal work fixes an arithmetic mismatch.

What is the Enhancing Oncology Model and does it change billing?

It is a CMS Innovation Center payment model built on six-month episodes triggered by chemotherapy across seven cancer types. Participating practices receive a Monthly Enhanced Oncology Services payment, which rose from $70 to $110 per beneficiary per month effective January 1, 2025, with a further $30 for dually eligible beneficiaries, and they carry performance-based accountability for the total cost of the episode. It changes billing in two ways. The monthly payment has to be billed and tracked like any other revenue stream, and the episode reconciliation keys off the claim data your billing operation produces, so participation reporting is a revenue cycle obligation rather than only a clinical one. Both cohorts run to June 30, 2030.

Free 30-day audit for oncology billing providers.

Send us your last 90 days of claim data. We assess realization, denial patterns, and operational discipline. Written 4-page report yours to keep.

Request audit →Talk to a senior partner

Oncology billing by state.

Dedicated Oncology billing and credentialing field guides for 49 states. Each state guide opens into its city-level guides with local payer, Medicaid, and credentialing detail.